Synergy Pharmaceuticals Inc (SGYP) 3.80 $SGYP
Synergy Pharmaceuticals to Give Plenary Presentation at the 16th Annual TIDES Summit
Business Wire - Mon May 12, 9:26AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), today announced its Chief Scientific Officer, Kunwar Shailubhai, PhD, MBA, will give a plenary presentation at the 16th Annual TIDES Summit being held May 12-15, in Providence Rhode Island.
Technical Recap on Biotech Equities -- Research on Hemispherx Biopharma, Orexigen Therapeutics, Dynavax Technologies, and Synergy Pharma
PR Newswire - Thu May 08, 1:30PM CDT
On Wednesday, May 07, 2014, the NASDAQ Composite ended at 4,067.67, down 0.32%, the Dow Jones Industrial Average finished the day 0.72% higher at 16,518.54, and the S&P 500 closed at 1,878.21, up 0.56%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.01, up 0.23%, and the index has advanced 0.50% in the last one month. Investor-Edge has initiated coverage on the following equities: Hemispherx Biopharma Inc. (NYSE MKT: HEB), Orexigen Therapeutics Inc. (NASDAQ: OREX), Dynavax Technologies Corporation (NASDAQ: DVAX) and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free technical research on HEB, OREX, DVAX and SGYP can be downloaded upon signing up at:
Irritable Bowel Syndrome - Pipeline Review, H1 2014: 29 Companies and 37 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/tqsgh4/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Alba Therapeutics Corporation - AlbireoPharma - Alfa Wassermann S.p.A - AltheRx Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Dainippon Sumitomo Pharma Co., Ltd. - Dong-A Socio Holdings Co Ltd - Drais Pharmaceuticals, Inc. - Furiex Pharmaceuticals, Inc. - GIcare Pharma Inc - Hanmi Pharmaceuticals, Co. Ltd. - ImmusanT, Inc. - Ironwood Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. - MicroDose Therapeutx, Inc. - Ono Pharmaceutical Co., Ltd. - ProMetic Life Sciences Inc. - Protagonist Therapeutics Inc. - RaQualia Pharma Inc. - Rottapharm|Madaus - SK Chemicals Co., Ltd. - Synergy Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Takeda Pharmaceutical Company Limited - Tioga Pharmaceuticals, Inc. - X-BODY BioSciences, Inc. - Yuhan Corporation Drug Profiles: - ramosetron - ibodutant - linaclotide - rifaximin - asimadoline - dexloxiglumide - eluxadoline - rifaximin - tenapanor - linaclotide - plecanatide - solabegron hydrochloride - elobixibat - ONO-2952 - LX-1033 - ASP-7147 - (mosapride Bacillus subtilis Streptococcas feacium) - DSP-6952 - SKI-3246 - SYN-010 - linaclotide - larazotide acetate - DA-6886 - YH-12852 - mexiletine hydrochloride - MDT-006 - RQ-00202730 - PBI-1737 - RQ-00310941 - GIC-1001 For more information visit http://www.researchandmarkets.com/research/tq...able_bowel
Synergy Pharmaceuticals to Present Data on SP-333 at Digestive Disease Week 2014
Business Wire - Thu May 01, 12:30PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that updated preclinical data on the company's second-generation uroguanylin analog, SP-333, will be presented during a poster session at Digestive Disease Week (DDW) in Chicago, May 3 - May 6, 2014.
Wednesday’s Top Health Care Stories: Auxilium, Johnson & Johnson, and Synergy
Leo Sun, The Motley Fool - Motley Fool - Wed Apr 30, 7:58AM CDT
Let's take a look at three stocks -- Auxilium Pharmaceuticals , Johnson & Johnson , and Synergy Pharmaceuticals -- which could all loom large in health care headlines this Wednesday morning. Auxilium lowers its full year guidance...
Why Synergy Pharmaceuticals (SGYP) Stock Is Surging This Morning
at The Street - Wed Apr 30, 7:22AM CDT
Shares of Synergy Pharmaceuticals (SGYP) are surging in pre-market trade after the company announced that its experimental constipation drug met the main goal of a mid-stage study in patients with a form of irritable bowel syndrome,
Synergy Pharmaceuticals Announces Positive Results of Plecanatide Phase 2b Study in Patients with Irritable Bowel Syndrome with Constipation
Business Wire - Wed Apr 30, 5:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced positive top-line results from a phase 2b dose-ranging study assessing plecanatide's safety and efficacy in 424 patients with irritable bowel syndrome with constipation (IBS-C). The primary objective of this trial was to determine an effective, safe and well tolerated dose for plecanatide phase 3 trials with IBS-C patients. Synergy is pleased to report this trial has achieved that objective. Preliminary analysis of the data indicates that plecanatide demonstrated statistically significant improvement in complete spontaneous bowel movement (CSBM) frequency - the study's primary endpoint - and was safe and well tolerated. Notably, patients taking the plecanatide 3.0mg dose experienced statistically significant improvement in change from baseline versus placebo in worst abdominal pain and met the FDA overall responder endpoint for IBS-C over the 12-week treatment. An overall responder for the FDA endpoint fulfills both greater-than or equal to30% reduction in worst abdominal pain and an increase of greater-than or equal to1 complete spontaneous bowel movements (CSBMs) from baseline in the same week for at least 50% of the weeks (i.e. 6/12 weeks).
Synergy Pharmaceuticals reports launch of second Phase 3 clinical trial of Plecanatide for chronic idiopathic constipation
M2 - Tue Apr 29, 6:25AM CDT
Biopharmaceutical company Synergy Pharmaceuticals (NasdaqGS:SGYP) said on Monday that it has commenced its second pivotal phase 3 clinical trial to confirm the safety and efficacy of plecanatide in adult patients with chronic idiopathic constipation (CIC).
Synergy Pharmaceuticals Initiates Second Phase 3 Clinical Trial of Plecanatide in Patients with Chronic Idiopathic Constipation
Business Wire - Mon Apr 28, 5:01AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced the start of its second pivotal phase 3 clinical trial to confirm the safety and efficacy of plecanatide, its lead uroguanylin analog and once-daily oral treatment, in adult patients with chronic idiopathic constipation (CIC).
Synergy Pharmaceuticals (SGYP) Jumps: Stock Up 10.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 8:39AM CDT
Synergy Pharmaceuticals, Inc. (SGYP) was a big mover last session, as its shares rose nearly 11% on the day.
Nasdaq stocks posting largest percentage increases
AP - Thu Apr 24, 12:28PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
ContraVir Strengthens Its Board of Directors with the Addition of Virology Expert, Scientist, and Entrepreneur, Timothy M. Block, Ph.D.
Business Wire - Wed Apr 23, 2:00PM CDT
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), an emerging biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that Timothy M. Block, Ph.D. has joined the company's Board of Directors. A renowned researcher and opinion leader in the field of virology, Dr. Block is a professor and founder of the Hepatitis B Foundation. His scientific work centers on the study and treatment of chronic viral infections including hepatitis B and C, and herpes simplex virus. Dr. Block has invented or co-invented several compounds designed to treat liver cancer and viral infection.
Global Opioid-Induced Constipation (OIC) Therapeutics Pipeline Review 2014 - Analysis of 11 Companes & 13 Drug Profiles
M2 - Wed Apr 23, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l3fs6f/opioidinduced) has announced the addition of the "Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opioid-Induced Constipation (OIC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opioid-Induced Constipation (OIC) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Opioid-Induced Constipation (OIC) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Opioid-Induced Constipation (OIC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Opioid-Induced Constipation (OIC) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - AstraZeneca PLC - Cubist Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Cosmo Pharmaceuticals S.p.A - Theravance, Inc. - Sucampo Pharmaceuticals, Inc. - AIKO Biotechnology, Inc. - Synergy Pharmaceuticals, Inc. - S.L.A. Pharma AG - Develco Pharma Schweiz AG Drug Profiles - naloxegol - lubiprostone - methylnaltrexone bromide - methylnaltrexone bromide - naldemedine - bevenopran - naloxone hydrochloride PR - methylnaltrexone bromide - TD-1211 - naloxone hydrochloride SR - SP-333 - naloxone hydrochloride - (6-beta-naltrexol oxycodone) For more information visit http://www.researchandmarkets.com/research/l3...oidinduced
Health Care Equities Analysis -- Research on Raptor Pharma, Intercept Pharma, KYTHERA Biopharma, and Synergy Pharma
PR Newswire - Tue Mar 25, 10:00AM CDT
On Monday, March 24, 2014, the NASDAQ Composite finished at 4,226.39, down 1.18%, the Dow Jones Industrial Average fell 0.16% to 16,276.69, and the S&P 500 closed at 1,857.44, down 0.49%. The losses were broad based with eight out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index finished the day at 666.18, down 1.41%, and the same has declined 2.67% in the last one month. Investor-Edge has initiated coverage on the following equities: Raptor Pharmaceutical Corp. (NASDAQ: RPTP), Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), KYTHERA Biopharmaceuticals Inc. (NASDAQ: KYTH) and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free technical research on RPTP, ICPT, KYTH and SGYP can be downloaded upon signing up at:
Synergy Pharmaceuticals Reports 2013 Fourth Quarter and Full-Year Financial Results
Business Wire - Mon Mar 17, 4:20PM CDT
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results and business update for the fourth quarter and the year ended December 31, 2013. Synergy is developing plecanatide for the treatment of chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C).
Synergy Pharmaceuticals Appoints Marino Garcia as Senior Vice President, Corporate Development
Business Wire - Thu Mar 13, 5:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today the appointment of Marino Garcia as Senior Vice President, Corporate Development. In this newly created position reporting directly to the CEO, Mr. Garcia will play a critical leadership role in Synergy's strategic corporate planning and business development activities.
Synergy Pharmaceuticals, Inc. (SGYP) Looks Good: Stock Adds 8.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 7:44AM CST
Synergy Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise nearly 9% on the day.
Synergy Pharmaceuticals' Chief Scientific Officer to Present Plenary Lecture at the 2014 Southern Regional Meetings
Business Wire - Wed Feb 19, 5:00AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced its Chief Scientific Officer, Kunwar Shailubhai, Ph.D., M.B.A., will present a plenary lecture entitled, "Cyclic GMP: Understanding its Evolution and Clinical Implications in Gastroenterology," during the Southern Gut Club meeting being held at the InterContinental New Orleans on Thursday, February 20, at 7:00pm (EST).
Synergy Pharmaceuticals to Present at Two Upcoming Investment Conferences
Business Wire - Mon Feb 03, 5:00AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that Chief Executive Officer, Gary S. Jacob, Ph.D., will present an overview of the company at two February investment conferences being held at the Waldorf Astoria in New York, N.Y.
Synergy Pharmaceuticals to Give Plenary Presentation at the 16th Annual TIDES Summit
Business Wire - Mon May 12, 9:26AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), today announced its Chief Scientific Officer, Kunwar Shailubhai, PhD, MBA, will give a plenary presentation at the 16th Annual TIDES Summit being held May 12-15, in Providence Rhode Island.
Technical Recap on Biotech Equities -- Research on Hemispherx Biopharma, Orexigen Therapeutics, Dynavax Technologies, and Synergy Pharma
PR Newswire - Thu May 08, 1:30PM CDT
On Wednesday, May 07, 2014, the NASDAQ Composite ended at 4,067.67, down 0.32%, the Dow Jones Industrial Average finished the day 0.72% higher at 16,518.54, and the S&P 500 closed at 1,878.21, up 0.56%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.01, up 0.23%, and the index has advanced 0.50% in the last one month. Investor-Edge has initiated coverage on the following equities: Hemispherx Biopharma Inc. (NYSE MKT: HEB), Orexigen Therapeutics Inc. (NASDAQ: OREX), Dynavax Technologies Corporation (NASDAQ: DVAX) and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free technical research on HEB, OREX, DVAX and SGYP can be downloaded upon signing up at:
Irritable Bowel Syndrome - Pipeline Review, H1 2014: 29 Companies and 37 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/tqsgh4/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Alba Therapeutics Corporation - AlbireoPharma - Alfa Wassermann S.p.A - AltheRx Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Dainippon Sumitomo Pharma Co., Ltd. - Dong-A Socio Holdings Co Ltd - Drais Pharmaceuticals, Inc. - Furiex Pharmaceuticals, Inc. - GIcare Pharma Inc - Hanmi Pharmaceuticals, Co. Ltd. - ImmusanT, Inc. - Ironwood Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. - MicroDose Therapeutx, Inc. - Ono Pharmaceutical Co., Ltd. - ProMetic Life Sciences Inc. - Protagonist Therapeutics Inc. - RaQualia Pharma Inc. - Rottapharm|Madaus - SK Chemicals Co., Ltd. - Synergy Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Takeda Pharmaceutical Company Limited - Tioga Pharmaceuticals, Inc. - X-BODY BioSciences, Inc. - Yuhan Corporation Drug Profiles: - ramosetron - ibodutant - linaclotide - rifaximin - asimadoline - dexloxiglumide - eluxadoline - rifaximin - tenapanor - linaclotide - plecanatide - solabegron hydrochloride - elobixibat - ONO-2952 - LX-1033 - ASP-7147 - (mosapride Bacillus subtilis Streptococcas feacium) - DSP-6952 - SKI-3246 - SYN-010 - linaclotide - larazotide acetate - DA-6886 - YH-12852 - mexiletine hydrochloride - MDT-006 - RQ-00202730 - PBI-1737 - RQ-00310941 - GIC-1001 For more information visit http://www.researchandmarkets.com/research/tq...able_bowel
Synergy Pharmaceuticals to Present Data on SP-333 at Digestive Disease Week 2014
Business Wire - Thu May 01, 12:30PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that updated preclinical data on the company's second-generation uroguanylin analog, SP-333, will be presented during a poster session at Digestive Disease Week (DDW) in Chicago, May 3 - May 6, 2014.
Wednesday’s Top Health Care Stories: Auxilium, Johnson & Johnson, and Synergy
Leo Sun, The Motley Fool - Motley Fool - Wed Apr 30, 7:58AM CDT
Let's take a look at three stocks -- Auxilium Pharmaceuticals , Johnson & Johnson , and Synergy Pharmaceuticals -- which could all loom large in health care headlines this Wednesday morning. Auxilium lowers its full year guidance...
Why Synergy Pharmaceuticals (SGYP) Stock Is Surging This Morning
at The Street - Wed Apr 30, 7:22AM CDT
Shares of Synergy Pharmaceuticals (SGYP) are surging in pre-market trade after the company announced that its experimental constipation drug met the main goal of a mid-stage study in patients with a form of irritable bowel syndrome,
Synergy Pharmaceuticals Announces Positive Results of Plecanatide Phase 2b Study in Patients with Irritable Bowel Syndrome with Constipation
Business Wire - Wed Apr 30, 5:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced positive top-line results from a phase 2b dose-ranging study assessing plecanatide's safety and efficacy in 424 patients with irritable bowel syndrome with constipation (IBS-C). The primary objective of this trial was to determine an effective, safe and well tolerated dose for plecanatide phase 3 trials with IBS-C patients. Synergy is pleased to report this trial has achieved that objective. Preliminary analysis of the data indicates that plecanatide demonstrated statistically significant improvement in complete spontaneous bowel movement (CSBM) frequency - the study's primary endpoint - and was safe and well tolerated. Notably, patients taking the plecanatide 3.0mg dose experienced statistically significant improvement in change from baseline versus placebo in worst abdominal pain and met the FDA overall responder endpoint for IBS-C over the 12-week treatment. An overall responder for the FDA endpoint fulfills both greater-than or equal to30% reduction in worst abdominal pain and an increase of greater-than or equal to1 complete spontaneous bowel movements (CSBMs) from baseline in the same week for at least 50% of the weeks (i.e. 6/12 weeks).
Synergy Pharmaceuticals reports launch of second Phase 3 clinical trial of Plecanatide for chronic idiopathic constipation
M2 - Tue Apr 29, 6:25AM CDT
Biopharmaceutical company Synergy Pharmaceuticals (NasdaqGS:SGYP) said on Monday that it has commenced its second pivotal phase 3 clinical trial to confirm the safety and efficacy of plecanatide in adult patients with chronic idiopathic constipation (CIC).
Synergy Pharmaceuticals Initiates Second Phase 3 Clinical Trial of Plecanatide in Patients with Chronic Idiopathic Constipation
Business Wire - Mon Apr 28, 5:01AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced the start of its second pivotal phase 3 clinical trial to confirm the safety and efficacy of plecanatide, its lead uroguanylin analog and once-daily oral treatment, in adult patients with chronic idiopathic constipation (CIC).
Synergy Pharmaceuticals (SGYP) Jumps: Stock Up 10.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 8:39AM CDT
Synergy Pharmaceuticals, Inc. (SGYP) was a big mover last session, as its shares rose nearly 11% on the day.
Nasdaq stocks posting largest percentage increases
AP - Thu Apr 24, 12:28PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
ContraVir Strengthens Its Board of Directors with the Addition of Virology Expert, Scientist, and Entrepreneur, Timothy M. Block, Ph.D.
Business Wire - Wed Apr 23, 2:00PM CDT
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), an emerging biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that Timothy M. Block, Ph.D. has joined the company's Board of Directors. A renowned researcher and opinion leader in the field of virology, Dr. Block is a professor and founder of the Hepatitis B Foundation. His scientific work centers on the study and treatment of chronic viral infections including hepatitis B and C, and herpes simplex virus. Dr. Block has invented or co-invented several compounds designed to treat liver cancer and viral infection.
Global Opioid-Induced Constipation (OIC) Therapeutics Pipeline Review 2014 - Analysis of 11 Companes & 13 Drug Profiles
M2 - Wed Apr 23, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l3fs6f/opioidinduced) has announced the addition of the "Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opioid-Induced Constipation (OIC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opioid-Induced Constipation (OIC) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Opioid-Induced Constipation (OIC) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Opioid-Induced Constipation (OIC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Opioid-Induced Constipation (OIC) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - AstraZeneca PLC - Cubist Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Cosmo Pharmaceuticals S.p.A - Theravance, Inc. - Sucampo Pharmaceuticals, Inc. - AIKO Biotechnology, Inc. - Synergy Pharmaceuticals, Inc. - S.L.A. Pharma AG - Develco Pharma Schweiz AG Drug Profiles - naloxegol - lubiprostone - methylnaltrexone bromide - methylnaltrexone bromide - naldemedine - bevenopran - naloxone hydrochloride PR - methylnaltrexone bromide - TD-1211 - naloxone hydrochloride SR - SP-333 - naloxone hydrochloride - (6-beta-naltrexol oxycodone) For more information visit http://www.researchandmarkets.com/research/l3...oidinduced
Health Care Equities Analysis -- Research on Raptor Pharma, Intercept Pharma, KYTHERA Biopharma, and Synergy Pharma
PR Newswire - Tue Mar 25, 10:00AM CDT
On Monday, March 24, 2014, the NASDAQ Composite finished at 4,226.39, down 1.18%, the Dow Jones Industrial Average fell 0.16% to 16,276.69, and the S&P 500 closed at 1,857.44, down 0.49%. The losses were broad based with eight out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index finished the day at 666.18, down 1.41%, and the same has declined 2.67% in the last one month. Investor-Edge has initiated coverage on the following equities: Raptor Pharmaceutical Corp. (NASDAQ: RPTP), Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), KYTHERA Biopharmaceuticals Inc. (NASDAQ: KYTH) and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free technical research on RPTP, ICPT, KYTH and SGYP can be downloaded upon signing up at:
Synergy Pharmaceuticals Reports 2013 Fourth Quarter and Full-Year Financial Results
Business Wire - Mon Mar 17, 4:20PM CDT
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results and business update for the fourth quarter and the year ended December 31, 2013. Synergy is developing plecanatide for the treatment of chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C).
Synergy Pharmaceuticals Appoints Marino Garcia as Senior Vice President, Corporate Development
Business Wire - Thu Mar 13, 5:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today the appointment of Marino Garcia as Senior Vice President, Corporate Development. In this newly created position reporting directly to the CEO, Mr. Garcia will play a critical leadership role in Synergy's strategic corporate planning and business development activities.
Synergy Pharmaceuticals, Inc. (SGYP) Looks Good: Stock Adds 8.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 7:44AM CST
Synergy Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise nearly 9% on the day.
Synergy Pharmaceuticals' Chief Scientific Officer to Present Plenary Lecture at the 2014 Southern Regional Meetings
Business Wire - Wed Feb 19, 5:00AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced its Chief Scientific Officer, Kunwar Shailubhai, Ph.D., M.B.A., will present a plenary lecture entitled, "Cyclic GMP: Understanding its Evolution and Clinical Implications in Gastroenterology," during the Southern Gut Club meeting being held at the InterContinental New Orleans on Thursday, February 20, at 7:00pm (EST).
Synergy Pharmaceuticals to Present at Two Upcoming Investment Conferences
Business Wire - Mon Feb 03, 5:00AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that Chief Executive Officer, Gary S. Jacob, Ph.D., will present an overview of the company at two February investment conferences being held at the Waldorf Astoria in New York, N.Y.
